GET DAILY SIGNALSWhy Is Ginkgo Bioworks Holdings (DNA) Stock Down -5.37% Today?
Key Takeaways
- DNA shares fell 5.37% to $9.70 in midday trading Wednesday, extending a sharp multi-day pullback from recent highs.
- The primary driver is a valuation reset and profit-taking after a speculative, AI-fueled rally pushed the stock to double-digit percentage gains in early November.
- Bearish analyst commentary—including a reiterated "Sell" rating with a $5.00 price target from BTIG Research—is weighing on sentiment.
- The move comes alongside relative weakness across life-science tools and diagnostics peers, a sector that has lagged broader market strength.
- Traders are watching whether the stock holds technical support, upcoming quarterly results, and progress on autonomous-lab commercialization.
- For additional details on valuation, results, and outlook, explore Price Targets, Earnings, and Forecast pages.
- To see how AI-driven strategies are navigating volatile names like this one, explore Trending AI Robots.
Opening Summary
Ginkgo Bioworks Holdings, Inc. (DNA) is a Boston-based synthetic-biology company that builds a cell-engineering platform, offering automated laboratory services, cloud-based lab access, and AI-powered research tools to customers across pharmaceuticals, agriculture, and industrial biotechnology. The stock traded down 5.37% at $9.70 during Wednesday's session, compared with a prior close of $10.25, confirming a continuation of the bearish reversal that began earlier this week. Markets attributed the decline primarily to profit-taking and a reassessment of the stock's valuation following an unusually volatile rally.
Profit-Taking After a Speculative Rally
The sharpest catalyst behind today's decline is a classic unwind of speculative momentum. DNA surged roughly 13% on November 6 and another 9.6% on November 9, driven by enthusiasm around its first autonomous-lab sale to a top-tier pharmaceutical company and broader AI-biotech optimism. Those gains proved difficult to sustain. The stock gave back 14.65% on November 11 and continued sliding Wednesday as short-term traders locked in profits and momentum faded. For a small-cap name with a beta well above 1.0 and elevated short interest, price swings of this magnitude are common once sentiment turns.
Bearish Analyst Ratings and Valuation Concerns
Fundamental skepticism has reinforced the downside. The analyst consensus on DNA sits at "Sell," with a consensus 12-month price target around $8.00—well below current levels. BTIG Research recently reiterated its own "Sell" rating with a $5.00 target, while several research notes have argued that the stock's valuation has run ahead of the underlying business. Because the company remains unprofitable and is still shrinking revenue, the post-rally valuation leaves little margin for error, making the shares vulnerable to downgrades and negative commentary.
Weak Fundamentals Beneath the Headlines
Even the company's third-quarter report, released November 5, painted a mixed picture. DNA beat expectations on adjusted earnings per share and revenue, and management affirmed its 2026 cash-burn target of $125 million to $150 million while announcing the autonomous-lab sale. However, revenue has been declining on a year-over-year basis, net losses remain substantial, and installations of new lab systems can take six to twelve months to convert into recurring revenue. Investors who initially celebrated the earnings beat are now weighing those lingering challenges, contributing to the stock's retreat.
Market Context and Trading Activity
Wednesday's move occurred on elevated trading volume relative to DNA's recent average, a sign of conviction selling rather than passive drift. The decline also aligned with relative softness across life-science tools and diagnostics names, suggesting a sector-level drag compounded company-specific concerns. Technically, the stock has slipped back below its 50-day moving average, and its 52-week range—from roughly $5.37 to $18.22—underscores how volatile and sentiment-driven the share price has become.
What Comes Next for DNA
Looking ahead, investors will monitor DNA's next quarterly results, expected in the early part of 2027, for evidence that autonomous-lab and cloud-lab bookings are translating into meaningful revenue. Key risks include continued cash burn, execution on new product installations, and the possibility of further analyst downgrades. Conversely, additional large-scale partnership or sales announcements could reignite momentum. Given the stock's history of outsized moves in both directions, traders should expect continued volatility around earnings and company announcements.
Trending AI Robots
Tickeron offers hundreds of AI trading bots covering thousands of tickers, but only the strongest performers under current market conditions are featured in the curated Trending AI Robots section. These bots vary by strategy, timeframe, performance metrics, and the symbols they trade, giving users a filtered view of AI-driven approaches that are currently outperforming. Traders interested in systematic, data-driven market analysis may find it useful to explore the page for actionable ideas.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
DNA sees its 50-day moving average cross bullishly above its 200-day moving average
The 50-day moving average for DNA moved above the 200-day moving average on October 07, 2026. This could be a long-term bullish signal for the stock as the stock shifts to an upward trend.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 60 of 68 cases where DNA's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 88%.
Following a +24.20% 3-day Advance, the price is estimated to grow further. Considering data from situations where DNA advanced for three days, in 209 of 248 cases, the price rose further within the following month. The odds of a continued upward trend are 84%.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on November 11, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on DNA as a result. In 81 of 86 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 90%.
The Moving Average Convergence Divergence Histogram (MACD) for DNA turned negative on November 11, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 51 similar instances when the indicator turned negative. In 47 of the 51 cases the stock turned lower in the days that followed. This puts the odds of success at 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where DNA declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
The Aroon Indicator for DNA entered a downward trend on November 10, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is 37 (best 1 - 100 worst), indicating steady price growth. DNA’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 41 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.809) is normal, around the industry mean (3.498). P/E Ratio (-2.258) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (3.397) is also within normal values, averaging (440.869).
The Tickeron PE Growth Rating for this company is 90 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. DNA’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry Biotechnology